Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer

Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer

To investigate the differences and relevance, and to evaluate the clinical significance of fluorescence in situ hybridisation and immunohistochemistry (IHC) in detecting HER2 in gastric cancer tissues. The expression of HER2 protein and the amplification of the HER2 gene in 118 gastric cancer tissue...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Contemporary oncology (Poznan, Poland) Poland), 2014-01, Vol.18 (2), p.95-99
Hauptverfasser: Chen, Ming, Li, Yan, Ming, Zhou, Biao, Ai, Zheng, Liu Xue
Format: Artikel
Sprache:eng
Schlagworte:
Original Paper
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 99
container_issue 2
container_start_page 95
container_title Contemporary oncology (Poznan, Poland)
container_volume 18
creator Chen, Ming
Li, Yan
Ming, Zhou
Biao, Ai
Zheng, Liu Xue
description To investigate the differences and relevance, and to evaluate the clinical significance of fluorescence in situ hybridisation and immunohistochemistry (IHC) in detecting HER2 in gastric cancer tissues. The expression of HER2 protein and the amplification of the HER2 gene in 118 gastric cancer tissues were detected by immunohistochemistry and fluorescence in situ hybridisation, respectively. Using IHC, we found that in 40 cases (33.9%) the HER2 expression was at level 0, in 33 cases (28.0%) the HER2 expression was at level 1+, in 16 cases (14%) the HER2 expression was at level 2+, and in 29 cases (25.6%) the HER2 expression was at level 3+, respectively. Using the FISH test, 38 of 118 cases (32.2%) were judged as positive results. The concordance rate between the results of IHC and FISH in all cases was 85.6%. The concordance rate of IHC and FISH was high in cases of HER2 expression at level 0, 1+ and 3+ according to IHC, but low in cases of 2+ according to IHC (43.8%). Immunohistochemistry cannot predict HER2 gene amplification accurately. The FISH test should be executed in IHC 2+ cases.
doi_str_mv 10.5114/wo.2014.41383
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4068816</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3331745241</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-9993506d7c5837b67d0db08a6a8347d684e729e0dac336501d01e58663a661be3</originalsourceid><addsrcrecordid>eNpVkUFLAzEQhYMoVmqPXiXgeWuyySbZiyClWqEgiJ5DNknblO6mJruW_femthY9zcB8782DB8ANRuMCY3q_8-McYTqmmAhyBq6wKHlGCSrP005zkeVFzgZgFKOrEMJcFIyQSzDIackYL_EVWE98vVXBRd9Av4Cz6VsOY6vaLsKqh4tN54ON2jbaQtfA6NoOrvoqOOOial0SqcZAV9dd41cutl6vbJ1m6Pf4UqXNaahV0odrcLFQm2hHxzkEH0_T98ksm78-v0we55kmHLdZWZakQMxwXQjCK8YNMhUSiilBKDdMUMvz0iKjNCGsQNggbAvBGFGM4cqSIXg4-G67qrYmhW-D2shtcLUKvfTKyf-Xxq3k0n9JipgQmCWDu6NB8J-dja1c-y40KbPERcqGCBYkUdmB0sHHGOzi9AEjuW9H7rzctyN_2kn87d9YJ_q3C_INeGqMeA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1535003183</pqid></control><display><type>article</type><title>Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Chen, Ming ; Li, Yan ; Ming, Zhou ; Biao, Ai ; Zheng, Liu Xue</creator><creatorcontrib>Chen, Ming ; Li, Yan ; Ming, Zhou ; Biao, Ai ; Zheng, Liu Xue</creatorcontrib><description>To investigate the differences and relevance, and to evaluate the clinical significance of fluorescence in situ hybridisation and immunohistochemistry (IHC) in detecting HER2 in gastric cancer tissues. The expression of HER2 protein and the amplification of the HER2 gene in 118 gastric cancer tissues were detected by immunohistochemistry and fluorescence in situ hybridisation, respectively. Using IHC, we found that in 40 cases (33.9%) the HER2 expression was at level 0, in 33 cases (28.0%) the HER2 expression was at level 1+, in 16 cases (14%) the HER2 expression was at level 2+, and in 29 cases (25.6%) the HER2 expression was at level 3+, respectively. Using the FISH test, 38 of 118 cases (32.2%) were judged as positive results. The concordance rate between the results of IHC and FISH in all cases was 85.6%. The concordance rate of IHC and FISH was high in cases of HER2 expression at level 0, 1+ and 3+ according to IHC, but low in cases of 2+ according to IHC (43.8%). Immunohistochemistry cannot predict HER2 gene amplification accurately. The FISH test should be executed in IHC 2+ cases.</description><identifier>ISSN: 1428-2526</identifier><identifier>EISSN: 1897-4309</identifier><identifier>DOI: 10.5114/wo.2014.41383</identifier><identifier>PMID: 24966791</identifier><language>eng</language><publisher>Poland: Termedia Publishing House</publisher><subject>Original Paper</subject><ispartof>Contemporary oncology (Poznan, Poland), 2014-01, Vol.18 (2), p.95-99</ispartof><rights>Copyright Termedia Publishing House 2014</rights><rights>Copyright © 2014 Termedia 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068816/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068816/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24966791$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Ming</creatorcontrib><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Ming, Zhou</creatorcontrib><creatorcontrib>Biao, Ai</creatorcontrib><creatorcontrib>Zheng, Liu Xue</creatorcontrib><title>Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer</title><title>Contemporary oncology (Poznan, Poland)</title><addtitle>Contemp Oncol (Pozn)</addtitle><description>To investigate the differences and relevance, and to evaluate the clinical significance of fluorescence in situ hybridisation and immunohistochemistry (IHC) in detecting HER2 in gastric cancer tissues. The expression of HER2 protein and the amplification of the HER2 gene in 118 gastric cancer tissues were detected by immunohistochemistry and fluorescence in situ hybridisation, respectively. Using IHC, we found that in 40 cases (33.9%) the HER2 expression was at level 0, in 33 cases (28.0%) the HER2 expression was at level 1+, in 16 cases (14%) the HER2 expression was at level 2+, and in 29 cases (25.6%) the HER2 expression was at level 3+, respectively. Using the FISH test, 38 of 118 cases (32.2%) were judged as positive results. The concordance rate between the results of IHC and FISH in all cases was 85.6%. The concordance rate of IHC and FISH was high in cases of HER2 expression at level 0, 1+ and 3+ according to IHC, but low in cases of 2+ according to IHC (43.8%). Immunohistochemistry cannot predict HER2 gene amplification accurately. The FISH test should be executed in IHC 2+ cases.</description><subject>Original Paper</subject><issn>1428-2526</issn><issn>1897-4309</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpVkUFLAzEQhYMoVmqPXiXgeWuyySbZiyClWqEgiJ5DNknblO6mJruW_femthY9zcB8782DB8ANRuMCY3q_8-McYTqmmAhyBq6wKHlGCSrP005zkeVFzgZgFKOrEMJcFIyQSzDIackYL_EVWE98vVXBRd9Av4Cz6VsOY6vaLsKqh4tN54ON2jbaQtfA6NoOrvoqOOOial0SqcZAV9dd41cutl6vbJ1m6Pf4UqXNaahV0odrcLFQm2hHxzkEH0_T98ksm78-v0we55kmHLdZWZakQMxwXQjCK8YNMhUSiilBKDdMUMvz0iKjNCGsQNggbAvBGFGM4cqSIXg4-G67qrYmhW-D2shtcLUKvfTKyf-Xxq3k0n9JipgQmCWDu6NB8J-dja1c-y40KbPERcqGCBYkUdmB0sHHGOzi9AEjuW9H7rzctyN_2kn87d9YJ_q3C_INeGqMeA</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Chen, Ming</creator><creator>Li, Yan</creator><creator>Ming, Zhou</creator><creator>Biao, Ai</creator><creator>Zheng, Liu Xue</creator><general>Termedia Publishing House</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BYOGL</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20140101</creationdate><title>Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer</title><author>Chen, Ming ; Li, Yan ; Ming, Zhou ; Biao, Ai ; Zheng, Liu Xue</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-9993506d7c5837b67d0db08a6a8347d684e729e0dac336501d01e58663a661be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Original Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Ming</creatorcontrib><creatorcontrib>Li, Yan</creatorcontrib><creatorcontrib>Ming, Zhou</creatorcontrib><creatorcontrib>Biao, Ai</creatorcontrib><creatorcontrib>Zheng, Liu Xue</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>East Europe, Central Europe Database</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Contemporary oncology (Poznan, Poland)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Ming</au><au>Li, Yan</au><au>Ming, Zhou</au><au>Biao, Ai</au><au>Zheng, Liu Xue</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer</atitle><jtitle>Contemporary oncology (Poznan, Poland)</jtitle><addtitle>Contemp Oncol (Pozn)</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>18</volume><issue>2</issue><spage>95</spage><epage>99</epage><pages>95-99</pages><issn>1428-2526</issn><eissn>1897-4309</eissn><abstract>To investigate the differences and relevance, and to evaluate the clinical significance of fluorescence in situ hybridisation and immunohistochemistry (IHC) in detecting HER2 in gastric cancer tissues. The expression of HER2 protein and the amplification of the HER2 gene in 118 gastric cancer tissues were detected by immunohistochemistry and fluorescence in situ hybridisation, respectively. Using IHC, we found that in 40 cases (33.9%) the HER2 expression was at level 0, in 33 cases (28.0%) the HER2 expression was at level 1+, in 16 cases (14%) the HER2 expression was at level 2+, and in 29 cases (25.6%) the HER2 expression was at level 3+, respectively. Using the FISH test, 38 of 118 cases (32.2%) were judged as positive results. The concordance rate between the results of IHC and FISH in all cases was 85.6%. The concordance rate of IHC and FISH was high in cases of HER2 expression at level 0, 1+ and 3+ according to IHC, but low in cases of 2+ according to IHC (43.8%). Immunohistochemistry cannot predict HER2 gene amplification accurately. The FISH test should be executed in IHC 2+ cases.</abstract><cop>Poland</cop><pub>Termedia Publishing House</pub><pmid>24966791</pmid><doi>10.5114/wo.2014.41383</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1428-2526
ispartof Contemporary oncology (Poznan, Poland), 2014-01, Vol.18 (2), p.95-99
issn 1428-2526
1897-4309
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4068816
source PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Original Paper
title Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T14%3A16%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20HER2%20status%20by%20fluorescence%20in%20situ%20hybridisation%20and%20immunohistochemistry%20in%20gastric%20cancer&rft.jtitle=Contemporary%20oncology%20(Poznan,%20Poland)&rft.au=Chen,%20Ming&rft.date=2014-01-01&rft.volume=18&rft.issue=2&rft.spage=95&rft.epage=99&rft.pages=95-99&rft.issn=1428-2526&rft.eissn=1897-4309&rft_id=info:doi/10.5114/wo.2014.41383&rft_dat=%3Cproquest_pubme%3E3331745241%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1535003183&rft_id=info:pmid/24966791&rfr_iscdi=true